Cargando…

Augmentation with antidepressants in schizophrenia treatment: benefit or risk

We focused on the application of antidepressants in schizophrenia treatment in this review. Augmentation of antidepressants with antipsychotics is a common clinical practice to treat resistant symptoms in schizophrenia, including depressive symptoms, negative symptoms, comorbid obsessive–compulsive...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Ye-Meng, Zhang, Ming-Dao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370910/
https://www.ncbi.nlm.nih.gov/pubmed/25834445
http://dx.doi.org/10.2147/NDT.S62266
_version_ 1782362960673374208
author Mao, Ye-Meng
Zhang, Ming-Dao
author_facet Mao, Ye-Meng
Zhang, Ming-Dao
author_sort Mao, Ye-Meng
collection PubMed
description We focused on the application of antidepressants in schizophrenia treatment in this review. Augmentation of antidepressants with antipsychotics is a common clinical practice to treat resistant symptoms in schizophrenia, including depressive symptoms, negative symptoms, comorbid obsessive–compulsive symptoms, and other psychotic manifestations. However, recent systematic review of the clinical effects of antidepressants is lacking. In this review, we have selected and summarized current literature on the use of antidepressants in patients with schizophrenia; the patterns of use and effectiveness, as well as risks and drug–drug interactions of this clinical practice are discussed in detail, with particular emphasis on the treatment of depressive symptoms in schizophrenia.
format Online
Article
Text
id pubmed-4370910
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-43709102015-04-01 Augmentation with antidepressants in schizophrenia treatment: benefit or risk Mao, Ye-Meng Zhang, Ming-Dao Neuropsychiatr Dis Treat Review We focused on the application of antidepressants in schizophrenia treatment in this review. Augmentation of antidepressants with antipsychotics is a common clinical practice to treat resistant symptoms in schizophrenia, including depressive symptoms, negative symptoms, comorbid obsessive–compulsive symptoms, and other psychotic manifestations. However, recent systematic review of the clinical effects of antidepressants is lacking. In this review, we have selected and summarized current literature on the use of antidepressants in patients with schizophrenia; the patterns of use and effectiveness, as well as risks and drug–drug interactions of this clinical practice are discussed in detail, with particular emphasis on the treatment of depressive symptoms in schizophrenia. Dove Medical Press 2015-03-16 /pmc/articles/PMC4370910/ /pubmed/25834445 http://dx.doi.org/10.2147/NDT.S62266 Text en © 2015 Mao and Zhang. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Mao, Ye-Meng
Zhang, Ming-Dao
Augmentation with antidepressants in schizophrenia treatment: benefit or risk
title Augmentation with antidepressants in schizophrenia treatment: benefit or risk
title_full Augmentation with antidepressants in schizophrenia treatment: benefit or risk
title_fullStr Augmentation with antidepressants in schizophrenia treatment: benefit or risk
title_full_unstemmed Augmentation with antidepressants in schizophrenia treatment: benefit or risk
title_short Augmentation with antidepressants in schizophrenia treatment: benefit or risk
title_sort augmentation with antidepressants in schizophrenia treatment: benefit or risk
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370910/
https://www.ncbi.nlm.nih.gov/pubmed/25834445
http://dx.doi.org/10.2147/NDT.S62266
work_keys_str_mv AT maoyemeng augmentationwithantidepressantsinschizophreniatreatmentbenefitorrisk
AT zhangmingdao augmentationwithantidepressantsinschizophreniatreatmentbenefitorrisk